Document Detail


Injectable hydrogel therapies and their delivery strategies for treating myocardial infarction.
MedLine Citation:
PMID:  23140533     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Heart failure following myocardial infarction (MI) impacts millions of people each year in the US. The field of tissue engineering has developed several potential therapies for treating MI including injectable acellular hydrogels. These injectable biomaterials can either be synthetic or naturally derived, and have the potential to be delivered minimally invasively.
AREAS COVERED: This review covers the different methods of delivery and presents the initial work on the use of injectable biomaterial scaffolds alone to improve cardiac function post-MI. Several naturally derived materials including alginate, collagen, chitosan, decellularized tissues, fibrin, hyaluronic acid, keratin, and Matrigel, as well as a few synthetic materials have shown promise on their own without the addition of therapeutics such as cells or growth factors. These biomaterials can be potentially delivered via endocardial, epicardial, or intracoronary injections and some can even utilize current catheter technology, indicating a potential for avoiding invasive surgical procedures. Once injected into the wall of the heart, these hydrogels create a scaffold that provides biochemical and structural cues, and the ability for cellular infiltration and remodeling of the local environment.
EXPERT OPINION: Injectable biomaterials have several crucial challenges that should be over come to design optimal therapies for MI and heart failure, including optimizing material properties, methods of injection and understanding the mechanisms of action. But, studies in both small and large animals have shown significant improvement in important parameters including wall thickness, vascularization of the ischemic region, left ventricular volumes, and cardiac function. Thus, the application of injectable biomaterials shows promise for developing into new therapies to treat MI, potentially improving millions of lives.
Authors:
Todd D Johnson; Karen L Christman
Related Documents :
20102093 - Gender differences in in-hospital mortality and angiographic findings of patients with ...
23874823 - N-acetylcysteine and allopurinol confer synergy in attenuating myocardial ischemia inju...
24412773 - The severity of coronary artery disease and reversible ischemia revealed by n-terminal ...
Publication Detail:
Type:  Journal Article; Review     Date:  2012-11-09
Journal Detail:
Title:  Expert opinion on drug delivery     Volume:  10     ISSN:  1744-7593     ISO Abbreviation:  Expert Opin Drug Deliv     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-19     Completed Date:  2013-07-03     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101228421     Medline TA:  Expert Opin Drug Deliv     Country:  England    
Other Details:
Languages:  eng     Pagination:  59-72     Citation Subset:  IM    
Affiliation:
University of California San Diego, Sanford Consortium of Regenerative Medicine, Department of Bioengineering, 2880 Torrey Pines Scenic Drive, La Jolla, CA 92037, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Biocompatible Materials / administration & dosage*,  chemistry
Chemistry, Pharmaceutical
Drug Delivery Systems*
Heart / drug effects*
Humans
Hydrogels / administration & dosage*,  chemistry
Injections
Myocardial Infarction / drug therapy*
Pharmaceutical Preparations / administration & dosage*,  chemistry
Tissue Engineering / methods
Chemical
Reg. No./Substance:
0/Biocompatible Materials; 0/Hydrogels; 0/Pharmaceutical Preparations

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Floral Markers of Cornflower (Centaurea cyanus) Honey and its Peroxide Antibacterial Activity for an...
Next Document:  Choline and betaine intake is inversely associated with breast cancer risk: A two-stage case-control...